Company intelligence / Profile preview

Sanavia Oncology

New York, New York, United Statessanavia.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Sanavia Oncology is developing novel immunotherapies targeting drug-resistant tumors. Its lead program SANA‑01 targets a novel epitope present in a majority of patients across several major solid tumor types. The company’s approach leverages advanced AI-driven target discovery and antibody engineering to generate highly specific therapeutics. No clinical results have been disclosed as of June 2025

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody-drug conjugateCAR-T cell therapyT cell engager (TCE)
Industry: Biotech

Drug pipeline

1 asset

SANA-01 ADC

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Sanavia Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanavia Oncology.

Explore the full profile